We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has granted approval for several generic versions of Boehringer Ingelheim’s osteoarthritis drug Mobic under the agency’s recently implemented “cluster” review policy, the agency said July 19.